Alzheimer; News from the web:
A drug called aducanumab could become the first approved treatment designed to alter the course of Alzheimer’s disease rather than relieve symptoms.
But it’s unclear whether the Food and Drug Administration will approve the drug because of persistent questions about its effectiveness.
Read all about it HERE
Alzheimer; News from the web:
A new approach to treat Alzheimer’s disease, potentially targeting the root cause of memory decline
There may be a trial near you check it out
Read all about it HERE
Alzheimer; News from the web:
In 2018, a research group led by David Holtzman, M.D., at Washington University in St. Louis developed an antibody drug in collaboration with Denali Therapeutics that showed promise as a potential Alzheimer’s disease therapy. Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab.
Read all about it HERE
Alzheimer; News from the web:
Read all about it HERE
Alzheimer; News from the web:
Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.
https://www.technologynetworks.com/
Read all about it HERE
Alzheimer; News from the web:
Listen to the podcast in our link for today to get a better appreciation of what the issues involved are.
Read all about it HERE